contents
Welcome to
Life Science Leader
M A R C H 2 014 V O L . 6 N O. 3
@
RFWrightLSL
linkedin.com/in/robertfwright pinterest.com/rfwrightlsl
facebook.com/LifeScienceLeader
W W W. LI FE S CI E N CE LE A D E R .CO M
LIFE SCIENCE LEADER (ISSN: 21610800) Vol. 6, No. 3 is published monthly by VertMarkets at Knowledge Park, 5340 Fryling Road,
Suite 300, Erie, PA 16510-4672. Phone (814) 897-9000, Fax (814) 899-5580. Periodical postage paid at Erie, PA 16510 and additional
mailing offices. Copyright 2014 by Peterson Partnership. All rights reserved. Printed in the USA.
SUBSCRIPTION RATES for qualified readers in the U.S. $0. For nonqualified readers in the U.S. and all other countries $97 for one
year. If your mailing address is outside the U.S. or Canada, you can receive the magazine digitally if you provide a valid email address.
POSTMASTER: Send address corrections (Form 3579) to Life Science Leader, Knowledge Park, 5340 Fryling Road, Suite 300, Erie, PA
16510-4672. PUBLICATIONS AGREEMENT No. 40722524 c/o AIM, 7289 Torbram Road, Mississauga, ON L4T 1G8
Columns: Insights:
Reports:
6
8
LIFESCIENCELEADER.COM MARCH 2014
4
Editor's Note
Editorial Advisory Board / Ask The Board
10
Capitol
Perspectives
Features:
42
JP Morgan
Conference
Review
Maintaining momentum — 2014
pharma and funding forecasts
I learned from Paul Janssen how
failures help you come to the solution.
Paul Stoffels, CSO of J&J; and worldwide chairman, Janssen
OUTSOURCING INSIGHTS | By Kate Hammeke
Trends In Outsourcing Solid Dose Manufacturing In 2014
BIO INNOVATION NOTES | By Eric Langer
Best Practices In Biomanufacturing Supplier Relations:
Reducing Raw Materials Risks
54
CLINICAL TRIALS
By Mukhtar Ahmed
Embracing M2M Technologies
To Transform Clinical Trials
50
CLINICAL TRIALS
By Nick Taylor
How Rare Disease Know-how
Can Shape Big Pharma
Clinical Trials
34
Life Science
Investment
Sage advice and sobering
cautions from Dennis Purcell,
senior managing partner
at Aisling Capital
28
Innovation
In Biotech
How Medicago is building a
new way to make vaccines
and proteins from tobacco
22
Cover Story:
J&J; / Janssen
18
14
12
Companies
To Watch
PHARMA BUSINESS
By Suzanne Elvidge
Nonantibiotics Spur Biotech-
Pharma Collaborations
58
78
74
LEADERSHIP LESSON
By Frauke Schorr, Ph.D.
4 Power-Thinking
Strategies of
Centered Leaders
INDUSTRY LEADER
By Matthias Steiert
How Patent Translation Can
Affect Your Bottom Line
BIOPHARM DEVELOPMENT &
MANUFACTURING
By K. John Morrow Jr., Ph.D.
Evolva Turns Around Its
Business Model: Swiss Biotech
Opts Out Of Drug Development
70
PHARMA MANUFACTURING
By Gail Dutton
Serialization – Pharma Faces
2015 Deadline
66
PHARMA BUSINESS
By Ed Miseta
Patient-centric Design:
The Next Frontier In Drug
Device Delivery
62
David Martin,
CEO and cofounder of AvidBiotics
"Antibiotic resistance
has emerged and has now
become rampant worldwide."
0 3 1 4 _ T O C _ F . i n d d 1 0314_TOC_F.indd 1 2 / 2 0 / 2 0 1 4 3 : 4 0 : 0 4 P M 2/20/2014 3:40:04 PM